Literature DB >> 2736200

Debrisoquine metabolism and genetic predisposition to lung cancer.

M R Law1, M R Hetzel, J R Idel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2736200      PMCID： PMC2247220          DOI： 10.1038/bjc.1989.142

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  9 in total

1.  Polymorphism of carbon oxidation of drugs and clinical implications.

Authors:  T P Sloan; A Mahgoub; R Lancaster; J R Idle; R L Smith
Journal:  Br Med J       Date:  1978-09-02

2.  Impairement of drug metabolism in tumor-bearing animals.

Authors:  R Rosso; M G Donelli; G Franchi; S Garattini
Journal:  Eur J Cancer       Date:  1971-12       Impact factor: 9.162

3.  Clinical pharmacology. Possible clinical importance of genetic differences in drug metabolism.

Authors:  D W Nebert
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-22

4.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

Authors:  D A Evans; A Mahgoub; T P Sloan; J R Idle; R L Smith
Journal:  J Med Genet       Date:  1980-04       Impact factor: 6.318

5.  A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin.

Authors:  E Steiner; L Iselius; G Alván; J Lindsten; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1985-10       Impact factor: 6.875

6.  The metabolism of [14C]-debrisoquine in man.

Authors:  J R Idle; A Mahgoub; M M Angelo; L G Dring; R Lancaster; R L Smith
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

7.  Polymorphic drug oxidation in humans.

Authors:  M Eichelbaum
Journal:  Fed Proc       Date:  1984-05-15

8.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer.

Authors:  R Ayesh; J R Idle; J C Ritchie; M J Crothers; M R Hetzel
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

9.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962
  9 in total
  14 in total

1.  Polymorphisms in oxidative drug metabolism: relationship to food preference.

Authors:  M R Britto; H E McKean; G G Bruckner; P J Wedlund
Journal:  Br J Clin Pharmacol       Date:  1991-08       Impact factor: 4.335

2.  The rationale for case-control methodology in epidemiological studies of cancer risk (response to Speirs et al., 1990)

Authors:  N Caporaso; J R Idle
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Debrisoquine oxidation phenotype and susceptibility to lung cancer.

Authors:  A R Boobis; D S Davies
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

4.  N-acetylation and debrisoquine hydroxylation polymorphisms in patients with Gilbert's syndrome.

Authors:  W Siegmund; J D Fengler; G Franke; M Zschiesche; O Eike; E Eike; P Meisel; R Wulkow
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

5.  The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.

Authors:  P M Christensen; P C Gøtzsche; K Brøsen
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

Review 6.  Molecular genetics of cytochrome P450 IID. Anomalies of drug metabolism.

Authors:  E Jacqz-Aigrain; S Panserat; L Sica; R Krishnamoorthy
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

7.  Mutant genes of cytochrome P-450IID6, glutathione S-transferase class Mu, and arylamine N-acetyltransferase in lung cancer patients.

Authors:  I Roots; J Brockmöller; N Drakoulis; R Loddenkemper
Journal:  Clin Investig       Date:  1992 Mar-Apr

8.  Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer.

Authors:  J M Ladero; J Benítez; J F González; E Vargas; M Díaz-Rubio
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Adolescent medical providers' willingness to recommend genetic susceptibility testing for nicotine addiction and lung cancer risk to adolescents.

Authors:  Suzanne C O'Neill; George Luta; Beth N Peshkin; Anisha Abraham; Leslie R Walker; Kenneth P Tercyak
Journal:  J Pediatr Psychol       Date:  2008-08-07

10.  Metabolism of debrisoquine and susceptibility to breast cancer.

Authors:  J Huober; B Bertram; E Petru; M Kaufmann; D Schmähl
Journal:  Breast Cancer Res Treat       Date:  1991-03       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.